Skip to main content
< Back to news
LIVERtera project, integrated by Doppl SA and BeCytes Biotechnologies. Image / BeCytes Biotechnologies
 14.03.2025

BeCytes Biotechnologies participates in LIVERtera, an innovative project to improve drug screening against liver tumors

The spinoff BeCytes Biotechnologies, based in the Barcelona Science Park, participates in LIVERtera, a pioneering initiative that combines in silico models and liver tumor organoids to accelerate the discovery of new oncological therapies. In collaboration with the Swiss company Doppl SA and with funding from the Center for Technological Development and Innovation (CDTI) and the Ministry of Science, Innovation and Universities, the project seeks to optimize drug screening using advanced technologies, improving the prediction of therapeutic efficacy and increasing success rates.

The development of effective treatments for liver cancer remains a challenge due to the complexity of tumor tissue and the difficulty in accurately replicating both its microenvironment and the behaviour of the human liver. The project LIVERtera (Integration of In Silico Models and Liver Tumor Organoids for the Identification and Validation of Therapeutic Targets) was created to tackle these challenges by combining the best of biotechnology and computational intelligence to accelerate the discovery of new cancer therapies.

In this context, BeCytes Biotechnologies and Doppl SA will work together to develop and optimize in vitro and in silico models for the study of liver tumors, encompassing the generation and cultivation of organoids, tissue characterization, and the development of advanced technologies.

A biotechnological leap in the fight against liver cancer

By integrating patient-derived liver tumor organoids with cutting-edge in silico models, LIVERtera aims to optimize drug screening, making it faster, more precise, and more representative of clinical reality.

This innovative strategy will allow the creation of a tumor organoid biobank for use in drug research and validation, the development of advanced in vitro and in silico models, and the establishment of an innovative preclinical service that integrates and optimizes drug screening by combining experimental and computational technologies.

By offering a more reliable and efficient system for selecting treatments, LIVERtera increases the success rate of clinical trials and fosters the development of more personalized and effective therapies. Additionally, the creation of an innovative preclinical service will enable faster and more meticulous drug screening, enhancing the clinical relevance of preclinical studies.

LIVERtera seeks to drive a disruptive change in precision oncology, promoting breakthroughs that will transform liver cancer treatment and benefit both patients and the scientific community.